The European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2014: a summary.
The European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2014: a summary.
复制标题
DOI：
10.1093/ckj/sfw135
复制
发表时间：
2017-04
影响因子：
4.6
通讯作者：
Stel VS
中科院分区：
文献类型：
--
作者：
Pippias M;Kramer A;Noordzij M;Afentakis N;Alonso de la Torre R;Ambühl PM;Aparicio Madre MI;Arribas Monzón F;Åsberg A;Bonthuis M;Bouzas Caamaño E;Bubic I;Caskey FJ;Castro de la Nuez P;Cernevskis H;de Los Ángeles Garcia Bazaga M;des Grottes JM;Fernández González R;Ferrer-Alamar M;Finne P;Garneata L;Golan E;Heaf JG;Hemmelder MH;Idrizi A;Ioannou K;Jarraya F;Kantaria N;Kolesnyk M;Kramar R;Lassalle M;Lezaic VV;Lopot F;Macario F;Magaz Á;Martín de Francisco AL;Martín Escobar E;Martínez Castelao A;Metcalfe W;Moreno Alia I;Nordio M;Ots-Rosenberg M;Palsson R;Ratkovic M;Resic H;Rutkowski B;Santiuste de Pablos C;Seyahi N;Fernanda Slon Roblero M;Spustova V;Stas KJF;Stendahl ME;Stojceva-Taneva O;Vazelov E;Ziginskiene E;Massy Z;Jager KJ;Stel VS
背景：本文总结了欧洲肾脏协会-欧洲透析和移植协会登记处2014年年度报告。它描述了2014年35个国家中终末期肾病（ESRD）的肾脏替代治疗（RRT）的流行病学。 研究方法：2016年，ERA-EDTA登记研究从51个国家或地区肾脏登记研究中收到了2014年接受RRT治疗ESRD的患者数据。32项登记研究提供了个体患者水平数据，19项登记研究提供了汇总患者水平数据。确定这些患者的发病率、患病率和生存概率。 结果：2014年，70953人开始接受RRT治疗ESRD，相当于总体未调整的发病率为每百万人口133人（pmp）。发病率范围为10倍;从乌克兰的23 pmp到葡萄牙的237 pmp。在开始RRT的患者中，近三分之二为男性，超过一半的患者年龄≥65岁，四分之一的患者的主要肾脏诊断为糖尿病。在开始RRT的第91天，81%的患者正在接受血液透析。2014年12月31日，490 743人接受了针对ESRD的RRT，相当于924 pmp的未校正患病率。整个欧洲的范围超过10倍，从乌克兰的157 pmp到葡萄牙的1794 pmp。2014年，共进行了19406例肾移植，相当于整体未经调整的移植率为36 pmp。这在整个欧洲又有很大的不同。对于2005-09年开始RRT的患者，所有RRT模式的5年校正患者生存概率为63.3%（95%置信区间63.0-63.6）。接受透析或肾移植的20- 24岁ESRD患者的预期剩余寿命分别为21.9年和44.0年。这大大低于20岁无ESRD患者的预期剩余寿命61.8年。
Background: This article summarizes the European Renal Association – European Dialysis and Transplant Association Registry’s 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2014 within 35 countries. Methods: In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51 national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated patient level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31 December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp. This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014, 19 406 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied considerably throughout Europe. For patients commencing RRT during 2005–09, the 5-year-adjusted patient survival probabilities on all RRT modalities was 63.3% (95% confidence interval 63.0–63.6). The expected remaining lifetime of a 20- to 24-year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD.